SCHEMBL4518804

SCHEMBL4518804

CCc1ccc(N(C)C)c(C(=O)N(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
MAPT P10636 3/20 0.43
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.39
TRPA1 O75762 1/20 0.37
METAP2 P50579 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CXCR1 P25024 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4508222 0.86 TRPA1 (0.37) ALDH1A1MAPTGAASMN1; SMN2TP53
SCHEMBL9400332 0.84 ALDH1A1 (0.53) ALDH1A1MAPTGAASMN1; SMN2TP53
SCHEMBL9970968 0.79 AR (0.45) ALDH1A1TP53TRPA1METAP2CXCR2
SCHEMBL14117285 0.77 TRPA1 (0.52) ALDH1A1TSHRTRPA1MEN1KMT2A
SCHEMBL4518802 0.77 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2TSHRMAPK1TRPA1
SCHEMBL19590684 0.77 HSPA5 (0.39) ALDH1A1GAASMN1; SMN2TSHRTRPA1
SCHEMBL16994789 0.77 ALDH1A1 (0.47) ALDH1A1MAPTGAASMN1; SMN2TP53
SCHEMBL4475121 0.76 PIK3CA (0.41) ALDH1A1SMN1; SMN2TRPA1KMT2AL3MBTL1
SCHEMBL4475971 0.76 ALDH1A1 (0.47) ALDH1A1MAPTSMN1; SMN2TP53MEN1
SCHEMBL17774831 0.75 GAA (0.49) ALDH1A1MAPTGAASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK ALDH1A1 780/4885MAPT 4633/4885GAA 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.